Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 21, 2019; 25(39): 6025-6040
Published online Oct 21, 2019. doi: 10.3748/wjg.v25.i39.6025
Published online Oct 21, 2019. doi: 10.3748/wjg.v25.i39.6025
Comparison | Side effect rate (%) | Heterogeneity | OR | 95%CI | P value | ||
Allicin group | Control | I2 (%) | P value | ||||
Allicin + PTT vs PTT[17-20] (ITT) | 7.38 | 13.51 | 6.66 | 0.36 | 0.52 | 0.22-1.20 | 0.125 |
Allicin + PTT vs PTT[17-20] (PP) | 5.92 | 9.57 | 0 | 0.59 | 0.61 | 0.32-1.16 | 0.132 |
Allicin-PPI-B-T-C vs PPI-B-T-C[21,22] (ITT/PP) | 4.49 | 5.77 | 0 | 0.69 | 0.77 | 0.28-2.13 | 0.612 |
Allicin-PPI-Am-F vs PPI-Am-F[18,20] (ITT/PP) | 2.27 | 7.95 | 0 | 0.85 | 0.27 | 0.054-1.34 | 0.110 |
- Citation: Si XB, Zhang XM, Wang S, Lan Y, Zhang S, Huo LY. Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis. World J Gastroenterol 2019; 25(39): 6025-6040
- URL: https://www.wjgnet.com/1007-9327/full/v25/i39/6025.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i39.6025